Patient group
Erwachsene mit mittelschwerer bis schwerer Prurigo nodularis, die für eine systemische Therapie in Betracht kommen
completed2025-02-15D series
Nemolizumab
Prurigo nodularis
Open official case page ↗
- Brand
- Nemluvio
- Manufacturer
- Galderma Laboratorium GmbH
G-BA action
final resolution
2025-08-07
Arzneimittel-Richtlinie/Anlage XII: Nemolizumab (Prurigo nodularis)
Evidence-checked summary
The G-BA found no proven added benefit for Erwachsene mit mittelschwerer bis schwerer Prurigo nodularis, die für eine systemische Therapie in Betracht kommen. The appropriate comparator was - Dupilumab. The G-BA issued a final resolution on 2025-08-07. The official page states that it took effect as follows: 07.08.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
This is the latest validated public action attached to this case. It is separate from the IQWiG assessment result.
Final benefit result
G-BA result by patient group
Official case record
What happened, in source order
No inferred stages
Consultation record
Oral hearing and Wortprotokoll
2025-06-23
27 parsed turns
Oral hearing: Nemolizumab (Prurigo nodularis)
Official Wortprotokoll · 7 pages
IQWiG comparison
Assessment record versus G-BA action
IQWiG assessment findings and the later G-BA action are separate records. Open both to compare them.
A25-31
matched
Nemolizumab (prurigo nodularis) – Benefit assessment according to §35a Social Code Book V
Official assessment PDF · 41 pages
G-BA decisions
Distinct actions and documents
2025-08-07
final resolution
Arzneimittel-Richtlinie/Anlage XII: Nemolizumab (Prurigo nodularis)
The G-BA found no proven added benefit for Erwachsene mit mittelschwerer bis schwerer Prurigo nodularis, die für eine systemische Therapie in Betracht kommen. The appropriate comparator was - Dupilumab. The G-BA issued a final resolution on 2025-08-07. The official page states that it took effect as follows: 07.08.2025. The page lists Arzneimittel-Richtlinie, Anlage XII: Nutzenbewertung nach § 35a SGB V as the normative target.
3 official documents · 4 cited claims
Official sources
Case document package
official case pageOfficial G-BA case pageOpen ↗comparator informationInformationen zur zweckmäßigen VergleichstherapieOpen ↗hearing transcriptWortprotokollOpen ↗decision textBeschlusstextOpen ↗decision rationaleTragende Gründe zum BeschlussOpen ↗summary documentationZusammenfassende DokumentationOpen ↗iqwig assessmentNutzenbewertung IQWiGOpen ↗